Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study.

Shuhei NagashimaSatoshi KobayashiShotaro TsunodaYui YamachikaYuichiro TozukaTaito FukushimaManabu MorimotoMakoto UenoJunji FuruseShin Maeda

Published in: International journal of clinical oncology (2023)

The efficacy and safety of nal-IRI + 5-FU/LV for patients with PDAC are not significantly different for those aged ≥ 70 years compared to younger patients.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
patient reported outcomes